DCTN2 and breast cancer: The upregulated expression of dynactin's subunit 2 (DCTN2) and subunit 5 (DCTN5) predicts the metastatic aggressiveness of breast cancer in patients (Figure 1b).[27] Analysis of the progression of breast cancer metastatic aggressiveness also conveys an incremental correlation between cancer stage progression and the overexpression of dynactin's subunit 2 (DCTN2) and dynein heavy chain 1 (DYNC1H1) (Figure 1c).[27] Thus, the analyzed data motivates additional experiments for unraveling the potential role of microtubule motors in breast cancer metastasis.